Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. (Q54452862)

30 May 2018

title

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. (English)

1 reference

30 May 2018

author name string

Ana L Basquiera

1

1 reference

30 May 2018

Néstor W Soria

2

1 reference

30 May 2018

Ricardo Ryser

3

1 reference

30 May 2018

Miriam Salguero

4

1 reference

30 May 2018

Beatriz Moiraghi

5

1 reference

30 May 2018

Federico Sackmann

6

1 reference

30 May 2018

Ana G Sturich

7

1 reference

30 May 2018

Adriana Borello

8

1 reference

30 May 2018

Adriana Berretta

9

1 reference

30 May 2018

Miriam Bonafé

10

1 reference

30 May 2018

José Moreno Barral

11

1 reference

30 May 2018

Emilio D Palazzo

12

1 reference

30 May 2018

Juan J García

13

1 reference

30 May 2018

publication date

1 December 2009

1 reference

30 May 2018

published in

Hematology

1 reference

30 May 2018

volume

14

1 reference

30 May 2018

issue

6

1 reference

30 May 2018

page(s)

323-330

1 reference

30 May 2018

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

cites work

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythem

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453309X12473408860226

10.1179/102453309X12473408860226

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

PubMed ID

19941738

1 reference

30 May 2018